These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24217803)

  • 1. What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?
    Blaslov K; Katalinic L; Kes P; Spasovski G; Smalcelj R; Basic-Jukic N
    Int Urol Nephrol; 2014 May; 46(5):1019-24. PubMed ID: 24217803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease.
    Westenfeld R; Schlieper G; Wöltje M; Gawlik A; Brandenburg V; Rutkowski P; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2011 Dec; 26(12):4115-23. PubMed ID: 21622987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia.
    Sessa A; Esposito A; Iavicoli GD; Lettieri E; Dente G; Costa C; Bergallo M; Rossano R; Capuano M
    Transplant Proc; 2010 May; 42(4):1148-55. PubMed ID: 20534247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
    Chadban SJ; Eris JM; Kanellis J; Pilmore H; Lee PC; Lim SK; Woodcock C; Kurstjens N; Russ G;
    Transpl Int; 2014 Mar; 27(3):302-11. PubMed ID: 24279685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
    Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
    de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
    Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19.
    Requião-Moura LR; Modelli de Andrade LG; de Sandes-Freitas TV; Cristelli MP; Viana LA; Nakamura MR; Garcia VD; Manfro RC; Simão DR; Almeida RAMB; Ferreira GF; Costa KMAH; de Lima PR; Pacheco-Silva A; Charpiot IMMF; Deboni LM; Ferreira TCA; Mazzali M; Calazans CAC; Oriá RB; Tedesco-Silva H; Medina-Pestana J;
    Transplantation; 2022 Oct; 106(10):e441-e451. PubMed ID: 35765133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.